SH2D3A

Across TCGA pan-cancer cohorts, SH2D3A mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SH2D3A data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SH2D3A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SH2D3A expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where SH2D3A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.795	0.291	.003	9	view →
CCRCC	OS	Median	III,IV	0.985	0.237	.017	7	view →
LUAD	DFS	Quartile	All	0.299	0.624	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SH2D3A–PDAC (OS)

Open the PDAC breakdown →